Sun Pharmaceuticals traded at 916.85 this Wednesday September 28th, increasing 19.70 or 2.20 percent since the previous trading session. Looking back, over the last four weeks, Sun Pharmaceuticals gained 4.28 percent. Over the last 12 months, its price rose by 13.01 percent. Looking ahead, we forecast Sun Pharmaceuticals to be priced at 896.91 by the end of this quarter and at 818.59 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
916.85
Daily Change
2.20%
Yearly
13.01%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Sh Fosun Pharma 29.56 -0.89 -2.92% -43.21%
Jiangsu Hengrui Me. 33.47 -0.18 -0.53% -32.95%
Aspen Pharmacare 13,583.00 183.00 1.37% -49.69%
Bharat Petroleum 308.85 -1.80 -0.58% -29.31%
Cipla 1,093.95 -4.75 -0.43% 10.77%
Dr.Reddys Laboratories 4,254.00 72.40 1.73% -12.85%
Reliance Infra 2,347.20 -49.05 -2.05% -7.15%
Sun Pharmaceuticals 916.85 19.70 2.20% 13.01%
UPL 668.30 -9.40 -1.39% -6.81%

Indexes Price Day Year
SENSEX 56598 -509.24 -0.89% -4.74%
NIFTY 50 16859 -148.80 -0.87% -4.81%

Sun Pharmaceuticals
Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.